Enjoy 12 digital issues a year from the global design authority Choose a print or digital subscription, or both ...

Australian researchers are turning to nature for the next computing revolution, harnessing living cells and biological ...

One company value investors might notice is Puma Biotechnology (PBYI). PBYI is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. PBYI is also sporting a PEG ratio of 1.38.

Unlike Trump’s first term, the pharmaceutical industry is in far more peril than it has ever been in, and the biotech industry needs to ask itself an important question: Where does it fit in ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Industry layoffs continue to accelerate, this time hitting RA Capital’s biotech incubator, according to Stat. RA Ventures, also known as Raven, is a healthcare accelerator for the prominent life ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating ... “We've really been inspired by GLP-1s, medicines that started in a group of diabetic patients that later expanded through ...

Here, as selected by the Wallpaper* style team, an assemblage of fashion and accessories both designed for, and inspired by, the garden – whether for the expert horticulturist or the pot-plant curious ...

University of Toronto spinout looks to fast-track drug formulation with machine learning and robotics. Toronto-based biotech Intrepid Labs has emerged from stealth with $11 million USD ($15.4 million ...

LONDON, May 14 (Reuters) - Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the ...

Engineers develop a liquid-based energy system inspired by the human body, offering efficient power for robots and chemical processes.

On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low ...